NeOnc Technologies Holdings, Inc. (NTHI) News
Follow NeOnc Technologies Holdings, Inc. (NTHI) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 32 public stories across 21 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
NeOnc Reports Third-Quarter 2026 Financial Results
NeOnc Technologies Holdings announced its third-quarter 2026 financial results; the supplied text provides no figures or clinical-progress details.
EQUITY | Nov 05, 2026, 02:03 PM UTC
M
NeOnc Technologies Reports Zero Revenue, $0.28 EPS Loss in 3Q 2026
NeOnc reported no revenue in the third quarter of 2026 and an EPS loss of $0.28. Its net loss attributable to common stockholders narrowed year over year.
EARNINGS | Nov 05, 2026, 01:41 PM UTC
L
NeOnc reports NEO100 compassionate-use milestone
A child showed early improvement, according to the headline.
EQUITY | Oct 16, 2026, 12:56 PM UTC
L
NeOnc Reports Early Clinical Improvement in First NEO100 Patient
NeOnc reports early clinical improvement in the first child treated with NEO100 under compassionate use in Abu Dhabi.
EQUITY | Oct 16, 2026, 12:00 PM UTC
L
NeOnc Technologies to meet FDA Nov. 17 for End-of-Phase 1 discussion on NEO212
NeOnc Technologies announced an in-person End-of-Phase 1 Type B meeting with the FDA on Nov. 17, 2026 to discuss NEO212 development.Key Highlights:Original SEC Filing: NEONC TECHNOLOGIES HOLDINGS, INC. [ NTHI ] - 8-K - S
REGULATION | Sep 28, 2026, 09:18 PM UTC
L
NeOnc Technologies Announces FDA End of Phase 1 Meeting for NEO212
November 17 meeting will address Phase 2 study design and potential regulatory pathwaysCALABASAS, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a
REGULATION | Sep 28, 2026, 02:03 PM UTC
L
NeOnc Technologies Initiated at Buy by Roth Capital
Ratings actions from Benzinga: GMT) NeOnc Technologies Price Target Announced at $20.00/Share by Roth CapitalRatings actions from Benzinga
NEWS | Sep 24, 2026, 06:25 PM UTC
L
NTHI - NeOnc Lands New Coverage and Roth Sees Potential 2026 Trial Catalyst
NTHI - NeOnc Lands New Coverage and Roth Sees Potential 2026 Trial Catalyst
NEWS | Sep 24, 2026, 02:20 PM UTC
L
NTHI - NeOnc’s Delivery may Finally Change the Equation for Brain Cancer ’s Next Frontier
NTHI - NeOnc’s Delivery may Finally Change the Equation for Brain Cancer ’s Next Frontier
NEWS | Sep 22, 2026, 06:52 PM UTC
L
NTHI - NeOnc Charting New Nasal Route to Treating Brain Cancer
NTHI - NeOnc Charting New Nasal Route to Treating Brain Cancer
NEWS | Sep 21, 2026, 12:00 PM UTC
L
NTHI - NeOnc Technologies Redeems All Outstanding Series A Convertible Preferred Stock and Eliminates Related Potential Dilution
NTHI - NeOnc Technologies Redeems All Outstanding Series A Convertible Preferred Stock and Eliminates Related Potential Dilution
EQUITY | Sep 17, 2026, 12:00 PM UTC
L
NTHI - NeOnc’s $629K Insider Buying Spree Follows Breakthrough Data and Now All Eyes Turn to the FDA
NTHI - NeOnc’s $629K Insider Buying Spree Follows Breakthrough Data and Now All Eyes Turn to the FDA
REGULATION | Sep 16, 2026, 12:46 PM UTC
L
NTHI - NeOnc Executives Invest Approximately $629,000 in Open-Market Stock Purchases Following Positive NEO100 Phase 2a Results
NTHI - NeOnc Executives Invest Approximately $629,000 in Open-Market Stock Purchases Following Positive NEO100 Phase 2a Results
EQUITY | Sep 16, 2026, 12:00 PM UTC
L
NTHI - Investor Determination to Beat Cancer Puts NeOnc’s Novel Therapies and Patented Platform in Focus
NTHI - Investor Determination to Beat Cancer Puts NeOnc’s Novel Therapies and Patented Platform in Focus
NEWS | Sep 15, 2026, 01:53 PM UTC
M
NeOnc Technologies raises about $15 million via registered direct offering at $4.20
NeOnc Technologies entered securities purchase agreements for a registered direct offering expected to raise approximately $15 million. The offering prices common shares and accompanying warrants at $4.20 and includes 2,
EQUITY | Sep 10, 2026, 02:34 PM UTC
L
NeOnc Technologies prices $15 mln at-the-market offering
NeOnc Technologies Holdings priced a $15 million at-the-market offering.
EQUITY | Sep 09, 2026, 04:43 PM UTC
L
NeOnc raises $15 million at market, adding fuel to NEO100 data
NeOnc (NTHI) raised $15 million at market.
EQUITY | Sep 09, 2026, 01:35 PM UTC
M
NeOnc Technologies prices $15M registered direct offering
NeOnc Technologies Holdings, Inc. priced a $15 million registered direct offering under Nasdaq at-the-market rules.
EQUITY | Sep 09, 2026, 12:02 PM UTC
L
NTHI - NeOnc' Phase 2 Data Could Put Cancer on the Ropes
NTHI - NeOnc' Phase 2 Data Could Put Cancer on the Ropes
EQUITY | Sep 08, 2026, 12:39 PM UTC
L
BTIG maintains $15.00 price target on NeOnc Technologies
BTIG maintained a $15.00/share price target on NeOnc Technologies, according to Benzinga ratings actions.
EQUITY | Sep 08, 2026, 10:57 AM UTC
L
NTHI - NeOnc’s Phase 2A Success Could Set the Stage for Something Much Bigger
NTHI - NeOnc’s Phase 2A Success Could Set the Stage for Something Much Bigger
EQUITY | Aug 28, 2026, 02:08 PM UTC
L
NTHI - NeOnc’s Clinical Story Is Now the Main Event
NTHI - NeOnc’s Clinical Story Is Now the Main Event
EQUITY | Aug 26, 2026, 01:39 PM UTC
L
NeonC Technologies CEO Amir F P Heshmatpour files Form 4P
NeonC Technologies Holdings, Inc. reports a Form 4P filing for CEO, President Amir F P Heshmatpour indicating 9,000 shares at $5.54 for $49,860.
EQUITY | Aug 18, 2026, 06:32 PM UTC
L
NTHI - NeOnc Technologies- Talk Is Cheap, Insider Buying Isn’t
NTHI - NeOnc Technologies- Talk Is Cheap, Insider Buying Isn’t
EQUITY | Aug 18, 2026, 02:18 PM UTC
L
NTHI - NTHI’s Nasdaq Advantage Takes on New Meaning After Its Breakthrough Phase 2a Results
NTHI - NTHI’s Nasdaq Advantage Takes on New Meaning After Its Breakthrough Phase 2a Results
EQUITY | Aug 17, 2026, 12:45 PM UTC
L
NTHI - The Nose Knows: Why NeOnc’s Patent Portfolio Could Make NTHI More Than a One-Drug Biotech
NTHI - The Nose Knows: Why NeOnc’s Patent Portfolio Could Make NTHI More Than a One-Drug Biotech
EQUITY | Aug 13, 2026, 06:31 PM UTC
L
NTHI - Targeting The Mutant: NTHI’s NEO100 Data Could Open a New Front in the Fight Against Brain Cancer
NTHI - Targeting The Mutant: NTHI’s NEO100 Data Could Open a New Front in the Fight Against Brain Cancer
EQUITY | Aug 12, 2026, 01:38 PM UTC
M
NTHI Trading Resumes
NTHI will resume at 8:30 am
EQUITY | Aug 12, 2026, 12:04 PM UTC
H
NTHI Reports Positive Phase 2a Results
NTHI reports positive topline Phase 2a results for Intranasal NEO100
EQUITY | Aug 12, 2026, 12:00 PM UTC
L
NTHI - NeOnc Technologies Appoints Strategy and Finance Executive Nasim Shomali to its Board of Directors
NTHI - NeOnc Technologies Appoints Strategy and Finance Executive Nasim Shomali to its Board of Directors
EQUITY | Jul 27, 2026, 01:00 PM UTC
H
NTHI Gains Momentum
NTHI builds regulatory momentum with 4 new research reports and UAE/Dubai drug approval ahead of Phase 2 data
EQUITY | Jun 24, 2026, 12:45 PM UTC
M
NTHI Receives UAE IND Approval
NeOnc Technologies receives UAE IND approval for NEO100, expanding global development ahead of anticipated Phase 2 data milestone
EQUITY | Jun 23, 2026, 01:01 PM UTC